[Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review].
Schmerz (Berlin, Germany) · 2016
Anabasum is a synthetic analog of Δ -tetrahydrocannabinol (THC)-11-oic acid that in preclinical models of experimental inflammation exerts potent anti-inflammatory actions with minimal central nervous system (CNS) cannabimimetic activity. Here we used a novel model of acute inflammation driven by i.d. UV-killed E. coli in healthy humans and found that anabasum (5 mg) exerted a potent anti-inflammatory effect equivalent to that of prednisolone in terms of inhibiting neutrophil infiltration, the hallmark of acute inflammation. These effects arose from the inhibition of the neutrophil chemoattractant LTB , while the inhibition of antiphagocytic prostanoids (PGE , TxB , and PGF α) resulted in enhanced clearance of inflammatory stimulus from the injected site. Anabasum at the higher dose of 20 mg possessed the additional properties of triggering the biosynthesis of specialized pro-resolving lipid mediators including LXA , LXB , RvD1, and RvD3. Collectively, we demonstrate for the first time a striking anti-inflammatory and pro-resolution effects of a synthetic analog of THC in healthy humans.
Schmerz (Berlin, Germany) · 2016
Journal of affective disorders · 2015
Autoimmunity reviews · 2016
Journal of pediatric gastroenterology and nutrition · 2017
The Clinical journal of pain · 2017
European archives of psychiatry and clinical neuroscience · 2017